|
14 Companies |
|
10 Products |
|
10 Products |
|
15 Mechanisms of Action |
|
0 Trials |
|
108 News |
|
| 123» |
- | Trial completion, Trial primary completion date: a4b7 Integrin in Eosinophilic Esophagitis (clinicaltrials.gov) - Feb 21, 2019
P=N/A, N=16, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Dec 2018
- | Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis (clinicaltrials.gov) - Jan 30, 2019
P=N/A, N=28, Completed, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Dec 2018 Recruiting --> Completed | N=50 --> 28 | Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2018
- | Trial completion, Phase classification, Trial completion date: Study to Image the Esophagus Using the OFDI Capsule (clinicaltrials.gov) - Dec 5, 2018
P=N/A, N=54, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=50 --> 28 | Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2018 Recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Oct 2018 --> Jul 2016
- | Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Trial completion date, Trial termination, Trial primary completion date: Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. (clinicaltrials.gov) - Oct 17, 2018
P2, N=40, Terminated, Sponsor: Mogens Bove
Recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Oct 2018 --> Jul 2016 Trial completion date: Dec 2017 --> Sep 2018 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2018; Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included).
- | Trial completion, Trial completion date: Assessing Risk of Food Insecurity Within Households of Children With Food Allergy (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=650, Completed, Sponsor: Arkansas Children's Hospital Research Institute
Trial completion date: Dec 2017 --> Sep 2018 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2018; Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included). Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Aug 2018
- | Trial completion, Trial completion date, Trial primary completion date: Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) (clinicaltrials.gov) - Aug 24, 2018
P=N/A, N=27, Completed, Sponsor: University of North Carolina, Chapel Hill
Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Aug 2018 Enrolling by invitation --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018
- | Trial completion, Enrollment change, Trial primary completion date: Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids (clinicaltrials.gov) - Jul 18, 2018
P2/3, N=67, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Enrolling by invitation --> Completed | Trial completion date: Aug 2018 --> Apr 2018 | Trial primary completion date: Aug 2018 --> Apr 2018 Recruiting --> Completed | N=292 --> 67 | Trial primary completion date: Nov 2017 --> May 2018
- | Gastrocrom (cromolyn) / Viatris
Trial completion, Enrollment change, Trial primary completion date: Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis (clinicaltrials.gov) - May 4, 2018
P4, N=16, Completed, Sponsor: University of Tennessee
Recruiting --> Completed | N=292 --> 67 | Trial primary completion date: Nov 2017 --> May 2018 Recruiting --> Completed | N=24 --> 16 | Trial primary completion date: Dec 2015 --> Jul 2017
- | Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: a4b7 Integrin in Eosinophilic Esophagitis (clinicaltrials.gov) - Apr 6, 2018
P, N=16, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=24 --> 16 | Trial primary completion date: Dec 2015 --> Jul 2017 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P | Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Nov 2017 --> Jul 2018
- | Trial completion date, Trial primary completion date: Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) (clinicaltrials.gov) - Mar 22, 2018
P=N/A, N=30, Enrolling by invitation, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P | Trial completion date: Mar 2018 --> Dec 2018 | Trial primary completion date: Nov 2017 --> Jul 2018 Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: Mar 2018 --> Aug 2018
- | Trial primary completion date: Study to Image the Esophagus Using the OFDI Capsule (clinicaltrials.gov) - Jan 25, 2018
P1, N=54, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: May 2018 --> Aug 2018 | Trial primary completion date: Mar 2018 --> Aug 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- | Trial completion: Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis (clinicaltrials.gov) - Nov 20, 2017
P=N/A, N=8, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2017 --> Oct 2018 Active, not recruiting --> Completed
- | Enrollment change: Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=30, Enrolling by invitation, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed N=16 --> 30
- | Carafate (sucralfate) / AbbVie
Trial completion: EoE: The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis (clinicaltrials.gov) - Oct 11, 2017
P, N=3, Completed, Sponsor: Mayo Clinic
N=16 --> 30 Active, not recruiting --> Completed
- | Trial primary completion date: Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis (clinicaltrials.gov) - Jul 12, 2017
P=N/A, N=8, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Sep 2017
- | Xolair (omalizumab) / Roche, Novartis
Trial completion: Omalizumab to Treat Eosinophilic Gastroenteritis (clinicaltrials.gov) - Jun 30, 2017
P2, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed
- |||| cendakimab (CC-93538) / AbbVie, BMS
Trial completion: HEROES: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis (clinicaltrials.gov) - May 9, 2017
P2, N=100, Completed, Sponsor: Celgene
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=20, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016
- | Trial completion, Enrollment change, Trial primary completion date: Mucosal Impedance in Pediatric Population (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=127, Completed, Sponsor: Vanderbilt University
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016 Recruiting --> Completed | N=198 --> 127 | Trial primary completion date: Dec 2016 --> Sep 2016
- | fluticasone propionate ODT (APT-1011) / Ellodi Pharma
Enrollment change: A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021 (clinicaltrials.gov) - Feb 12, 2017
P1/2, N=14, Completed, Sponsor: Forest Laboratories
Recruiting --> Completed | N=198 --> 127 | Trial primary completion date: Dec 2016 --> Sep 2016 N=24 --> 14
- ||||||| Jorveza (budesonide orodispersible tablets) / Dr Falk
Trial completion, Trial primary completion date: EOS-1: Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis (clinicaltrials.gov) - Feb 3, 2017
P3, N=88, Completed, Sponsor: Dr. Falk Pharma GmbH
N=24 --> 14 Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Aug 2016
- Trial primary completion date: Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=16, Enrolling by invitation, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Aug 2016 Trial primary completion date: Mar 2017 --> Mar 2018
- Trial completion, Trial primary completion date: EoE(Eosinophilic Esophagitis) (clinicaltrials.gov) - Dec 16, 2016
P=N/A, N=10, Completed, Sponsor: University of Michigan
Trial primary completion date: Mar 2017 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Apr 2016
- Trial completion: CoFAR5: Eosinophilic Esophagitis Databank (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=709, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Apr 2016 Active, not recruiting --> Completed
- Enrollment closed, Enrollment change, Trial primary completion date: Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=8, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 8 | Trial primary completion date: May 2016 --> Jun 2017
- Trial primary completion date: Mucosal Impedance in Pediatric Population (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=198, Recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting | N=20 --> 8 | Trial primary completion date: May 2016 --> Jun 2017 Trial primary completion date: Jan 2016 --> Dec 2016
- Enrollment change, Trial termination, Trial primary completion date: Esophageal Absorption in EoE (clinicaltrials.gov) - Jul 24, 2016
P=N/A, N=14, Terminated, Sponsor: Mayo Clinic
N=40 --> 14 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2016; Early analysis showed negative results. It was decided to halt the study.
- Biomarker, Enrollment open: Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis (clinicaltrials.gov) - Jul 18, 2016
P=N/A, N=50, Recruiting, Sponsor: University of Wisconsin, Madison
It was decided to halt the study. Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal: Eosinophilic Gastrointestinal Disorders Patient Registry (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=0, Withdrawn, Sponsor: Arkansas Children's Hospital Research Institute
Not yet recruiting --> Recruiting N=1000 --> 0 | Enrolling by invitation --> Withdrawn
- || cendakimab (CC-93538) / AbbVie, BMS
Trial primary completion date: HEROES: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis (clinicaltrials.gov) - May 28, 2016
P2, N=90, Active, not recruiting, Sponsor: Celgene
N=1000 --> 0 | Enrolling by invitation --> Withdrawn Trial primary completion date: Jul 2016 --> Feb 2016
- Biomarker, New trial: Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis (clinicaltrials.gov) - May 18, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: University of Wisconsin, Madison
- | Xolair (omalizumab) / Roche, Novartis
Trial completion: A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab (clinicaltrials.gov) - May 18, 2016
P2, N=30, Completed, Sponsor: University of Utah
Trial primary completion date: Jul 2016 --> Feb 2016 Recruiting --> Completed
- Trial primary completion date: Study to Image the Esophagus Using the OFDI Capsule (clinicaltrials.gov) - Apr 18, 2016
P1, N=54, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2017
- Trial primary completion date: Assessing Risk of Food Insecurity Within Households of Children With Food Allergy (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=650, Enrolling by invitation, Sponsor: Arkansas Children's Hospital Research Institute
Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- New trial: Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=16, Enrolling by invitation, Sponsor: University of North Carolina, Chapel Hill
- Enrollment open, Trial initiation date: a4b7 Integrin in Eosinophilic Esophagitis (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=16, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Mar 2016
- Trial primary completion date: Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? (clinicaltrials.gov) - Mar 17, 2016
P=N/A, N=20, Enrolling by invitation, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Carafate (sucralfate) / AbbVie
Enrollment closed, Trial primary completion date: EoE: The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis (clinicaltrials.gov) - Mar 16, 2016
P0, N=6, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Feb 2017
- Enrollment closed: CoFAR5: Eosinophilic Esophagitis Databank (clinicaltrials.gov) - Mar 8, 2016
P=N/A, N=709, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Feb 2017 Recruiting --> Active, not recruiting
- |||||| Jorveza (budesonide orodispersible tablets) / Dr Falk
Enrollment open, Trial initiation date, Trial primary completion date: EOS-1: Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis (clinicaltrials.gov) - Jan 21, 2016
P3, N=90, Recruiting, Sponsor: Dr. Falk Pharma GmbH
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Nov 2015 | Trial primary completion date: Mar 2017 --> Sep 2017
- Trial primary completion date: Esophageal Absorption in EoE (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=40, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Nov 2015 | Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Dec 2015 --> Nov 2016
- Trial termination: Bethanechol for Eosinophilic Esophagitis (clinicaltrials.gov) - Jan 15, 2016
P2, N=2, Terminated, Sponsor: University of Iowa
Trial primary completion date: Dec 2015 --> Nov 2016 Completed --> Terminated; Initial PI left, study not continued
- | Enrollment open: Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids (clinicaltrials.gov) - Jan 5, 2016
P2/3, N=292, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Completed --> Terminated; Initial PI left, study not continued Not yet recruiting --> Recruiting
- Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Enrollment open, Trial primary completion date: Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. (clinicaltrials.gov) - Dec 21, 2015
P2, N=42, Enrolling by invitation, Sponsor: Mogens Bove
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Dec 2017
- Enrollment closed: EoE(Eosinophilic Esophagitis) (clinicaltrials.gov) - Dec 9, 2015
P=N/A, N=10, Active, not recruiting, Sponsor: University of Michigan
Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Dec 2017 Recruiting --> Active, not recruiting
- || New P2/3 trial: Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids (clinicaltrials.gov) - Nov 21, 2015
P2/3, N=292, Not yet recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
- Trial primary completion date: CoFAR5: Eosinophilic Esophagitis Databank (clinicaltrials.gov) - Oct 2, 2015
P=N/A, N=715, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Dec 2015
- | montelukast / Generic mfg.
Trial completion, Enrollment change: Trial of Montelukast in Eosinophilic Esophagitis (clinicaltrials.gov) - Sep 25, 2015
P1, N=41, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2015 --> Dec 2015 Recruiting --> Completed | N=60 --> 41
- ||| cendakimab (CC-93538) / AbbVie, BMS
Enrollment closed: HEROES: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis (clinicaltrials.gov) - Sep 17, 2015
P2, N=90, Active, not recruiting, Sponsor: Receptos, Inc.
Recruiting --> Completed | N=60 --> 41 Recruiting --> Active, not recruiting
- New trial: a4b7 Integrin in Eosinophilic Esophagitis (clinicaltrials.gov) - Sep 10, 2015
P=N/A, N=16, Not yet recruiting, Sponsor: Massachusetts General Hospital